€80.0M
The financing round was led by IQ Capital to accelerate clinical trials for glioblastoma and other solid tumours.
T
Trogenix
Developer of Trojan horse cancer therapies targeting aggressive solid tumours.
Edinburgh, UK—Founded 2023
€80.0MTotal raised
Scottish biotech developer utilising synthetic biology to engineer targeted cancer treatments.
Categories
Team
Ken Macnamara
Chief Executive Officer
Ken serves as chief executive officer at Trogenix, following operating and product leadership roles at Asklepios BioPharmaceutical and Synpromics.
LinkedInSP
Steve Pollard
Professor